3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Pancreatic Neoplasms
406
Carcinoma, Non-Small-Cell Lung
147
Urinary Bladder Neoplasms
87
Breast Neoplasms
84
Cholangiocarcinoma
83
Lung Neoplasms
78
Neoplasm Metastasis
67
Neoplasms
64
Biliary Tract Neoplasms
58
Nasopharyngeal Carcinoma
53
Ovarian Neoplasms
46
Sarcoma
43
Recurrence
39
Gallbladder Neoplasms
39
Hodgkin Disease
34
Lymphoma, Large B-Cell, Diffuse
33
Lymphoma
32
Carcinoma, Transitional Cell
29
Bile Duct Neoplasms
24
Adenocarcinoma
23
Fallopian Tube Neoplasms
19
Carcinoma, Hepatocellular
19
Adenocarcinoma of Lung
18
Triple Negative Breast Neoplasms
17
Lymphoma, Non-Hodgkin
17
Liver Neoplasms
17
Nasopharyngeal Neoplasms
16
Lymphoma, Extranodal NK-T-Cell
16
Carcinoma
16
Non-Muscle Invasive Bladder Neoplasms
15
Interventions
fludarabine
2
Paclitaxel
2
Nivolumab
2
Bevacizumab
2
rucaparib
1
liposomal doxorubicin
1
dostarlimab
1
Sunitinib
1
Stem Cell Transplantation
1
Sirolimus
1
Radiotherapy
1
Melphalan
1
Ipilimumab
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Doxorubicin
1
Dexamethasone
1
Celecoxib
1
Carboplatin
1
Capecitabine
1
Busulfan
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma, Clear Cell
×
Gemcitabine
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled